Skip to main content
SpringerLink
Log in
Book cover

Triazenes pp 133–144Cite as

Triazenes: Therapeutic Considerations and Perspectives

  • Chapter

Abstract

Since the first reports on the synthesis of triazenes at the end of last century, triazenes received a certain attention by chemists. The demonstration that phenyl- and imidazole-dimethyltriazenes caused antitumor effects in laboratory animals led to a wider examination of the biological and pharmacological properties of this class of compounds. As a result of these earlier studies, DTIC has entered the clinical practice as an antitumor agent active against malignant melanoma, soft tissue sarcomas, Hodgkin’s lymphoma, APUD cell tumors, and it has also been used less frequently on other solid tumors.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. J.A. Montgomery, Experimental studies at Southern Research Institute with DTIC (NSC45388), Cancer Treat. Rep. 60: 125 (1976).

    PubMed  CAS  Google Scholar 

  2. D.H. Cowan, and D.E. Bergsagel, Intermittent treatment of metastatic malignant melanoma with high dose 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC45388), Cancer Chemoter. Rep. 55: 175 (1971).

    CAS  Google Scholar 

  3. K.I. Pritchard, I.C. Quirt, D.H. Cowan, D. Osoba and, G.J. Kutas, DTIC therapy in metastatic malignant melanoma: a simplified dose schedule, Cancer Treat. Rep. 64: 1123 (1980).

    PubMed  CAS  Google Scholar 

  4. G.J. Hill, G.E. Metter, S.E. Moss, and F.M. Golomb, DTIC therapy for melanoma: correlation of toxicity with response and longevity in 742 patients, AACR Proc. 17: 244 (1976).

    Google Scholar 

  5. G.J. Hill, S.E. Moss, F.M. Golomb, and G.E. Metter, DTIC and combination therapy for melanoma, Cancer 47: 25 (1981).

    Article  Google Scholar 

  6. G.J. Hill, G.E. Metter, E.T. Krementz, W.S. Fletcher, F.M. Colomb, G. Ramirez, T.B. Grage, and S.E. Moss, DTIC and combination therapy for melanoma. II. Escalating schedule of DTIC with BCNU, CCNU and vincristine, Cancer Treat. Rep. 63: 19 (1979).

    Google Scholar 

  7. M.K. Samson, L.H. Baker, G. Cummings, R.W. Talley, B. McDonald, and D.B. Bhathena, Clinical trial of chlorozotocin, DTIC and dactinomycin in metastatic malignant melanoma, Cancer Treat. Rep. 66: 371 (1982).

    PubMed  CAS  Google Scholar 

  8. A. Kessinger, J.F. Foley, and, H.M. Lemon, Therapy of malignant APUD cell tumors. Effectiveness of DTIC, Cancer 51: 790 (1989).

    Article  Google Scholar 

  9. W. Blum, J.S. Greenberger, G.P. Canellos, and E. Frei, Successful treatment of metastatic sarcomas with cyclophosphamide, adriamycin and DTIC (CAD), Cancer 46: 1722 (1980).

    Article  PubMed  CAS  Google Scholar 

  10. L. Nathanson, J. Walter, and J. Horton, Characteristics of prognosis and response to an imidazole carboxamide in malignant melanoma, Clin. Pharmacol. Ther. 12: 955 (1979).

    Google Scholar 

  11. G.A. Van Hazel, J. Rubin, and, C.G. Moertel, Treatment of metastatic carcinoid tumor with dactinomycin or dacarbazine, Cancer Chemother. Rep. 67: 583 (1983).

    Google Scholar 

  12. E.C. Borden, D. Amato, H.T. Enterline, H. Lerner, and P.P. Carbone, Randomized comparison of adriamycin regi mens for treatment of metastatic soft tissue sarcomas, ASCO Proc. 2: 231 (1983).

    Google Scholar 

  13. J.A. Gottlieb, L.H. Baker, J.M. Quagliarla, J.K. Luce, J. P. Whitecar, J.C. Sinkovics, S.E. Rivkin, R. Brownlee, and E. Frei, Chemotherapy of sarcomas with a combination of adriamycin and DTIC, Cancer 30: 1632 (1972).

    Article  PubMed  CAS  Google Scholar 

  14. M. Lopez, S. Carpano, L. Di Lauro, P. Vici, and E.M.S. Conti, Treatment of advanced soft tissue sarcomas with epirubicin and DTIC, 5 th Europ. Conf. Clin. Oncol. ECCO5, London 3–5 sept. 1989, Abst. P-0462.

    Google Scholar 

  15. M.J. Mastrangelo, A.R. Baker, and H.R. Katz, Cutaneous melanoma, in: “Cancer principles and practice of oncology,” V.T. De Vita, S. Hellmann and S.A. Rosenberg, eds., II Edition, Lippincott, Philadelphia, 1371 (1985).

    Google Scholar 

  16. R. Oratz, J.L. Speyer, M.D. Green, R. Blum, J. Wernz, D. Roses, M. Harris, and F.M. Muggia, DTIC and cisplatinum chemotherapy in metastatic malignant melanoma, ASCO Proc. 6: 208 (1987).

    Google Scholar 

  17. C. Portlock, J. Murren, A. Buzaid, C. Davis, and W. DeRosa, High dose cisplatin and dacarbazine in metastatic melanoma, ASCO Proc. 8: 284 (1989)

    Google Scholar 

  18. J. Casal, A.J. Movano, C. Crespo, A. Marques, L. Carbanas, and R. Moreno, Ifosfamide and DTIC in metastatic malignant melanoma. An effective combination, 5 th Europ. Conf. Clin. Oncol. ECCO5, London 3–7 sept. 1989, Abst. P-0602

    Google Scholar 

  19. W. Campbell, O. Beloqui, P. Herranz, M. Santos, M. Sureda, V. Hidalgo, A. Gil, E. Barrajon, and F.A. Calvo, Ifosfamide, doxorubicin, dacarbazine and amphotericin B in metastatic soft tissue sarcoma: preliminary results of a phase II study, AACR Proc. 29: 222 (1988).

    Google Scholar 

  20. C. Charnsangavej, V.P. Chuang, S. Wallace, C.S. Soo, and T. Bowers, Angiographic appearance of recurrent malignant melanoma before and after intra-arterial chemotherapy, Radiology 142: 347 (1982).

    PubMed  CAS  Google Scholar 

  21. T.L. Loo, E.A. Strasswender, J.H. Jardine, and E. Frei III, Clinical pharmacological studies on 5-(dimethyltriazeno)-imidazole-4-carboxamide (NSC 45388), AACR Proc. 8: 42 (1967).

    Google Scholar 

  22. G. Cartei, T. Ceschia, P. Marsilio, L. Clocchiatti, G. Fasola, G. Morandini, D. Galletti, and A. Sibau, Effectiveness and toxicity of BELD polychemotherapy in advanced malignant melanoma, Tumori 75: 229 (1989).

    PubMed  CAS  Google Scholar 

  23. G. Cartei, A. Bononi, G. Interlandi, F. Cartei, and A. Cantone, Alizapride nell’antiemesi durante monochemioterapia con cis-DD-platino, Atti Sec. Congr. Naz. Soc. Ital. Cure Palliative, 16 dicembre 1989, p. 96.

    Google Scholar 

  24. J.K. Luce, W.G. Thurman, B.L. Isaacs, and R.W. Talley, Clinical trial with the antitumor agent 5-(dimethyltriazeno)imidazole-4-carboxamide (NSC 45388), Cancer Chemother. Rep. 54:119 (1970).

    PubMed  CAS  Google Scholar 

  25. F. Ley, M. Winzer, M. Weber, and M. Hypa, Budd-Chiari-Syndrom nach Dacarbacin (DTIC) therapie bei malignem Melanom — ein vermeidbarer Zwischenfall, Z. Hautkr. 60:961 (1985).

    Google Scholar 

  26. C. Erichsen and P-E. Jonsson, Venoocclusive disease after dacarbazine therapy (DTIC) for melanoma, J. Surg. Oncol. 27: 268 (1984).

    Article  PubMed  CAS  Google Scholar 

  27. H. Swensson-Beck and W.H. Trettel, Budd Chiari syndrom bei DTIC-therapie, Hauzart 33: 30 (1982).

    CAS  Google Scholar 

  28. E.F. McClay, M.J. Mastrangelo, R.E. Bellet, and D. Berd, An effective chemo hotmonal therapy regimen for the treatment of disseminated malignant melanoma, ASCO Proc., 6:208 821 (1987).

    Google Scholar 

  29. J.H. Paulusma-DeWaal, F.T. Bosman, H.R.A. Fischer, P.C. Van der Velden, and W.H.L. Hackeng, The glucagonoma syndrome, Neth. J. Med. 25: 127 (1982).

    CAS  Google Scholar 

  30. F.K. Storm, L.R. Kaiser, J.E. Goodnight, W. Harrtson, R.S. Helliott, P.H.D. Antoniette, S. Gomes, and D.L. Morton, Thermochemotherapy for melanoma metastases in liver, Cancer 49: 1243 (1982).

    Article  PubMed  CAS  Google Scholar 

  31. A. Franchi, S. D’Atri, E. Bonmassar, D. Piccioni, F. Mandelli, F. Malagnino, M. Masi, and G. Papa, High dose dacarbazine in acute leukemia: preliminary immunotoxicological studies, Farmaci e Terapia 5 (suppl. 5): 63, (1988)

    Google Scholar 

  32. G. Cocconi, M. Bella, F. Calabresi, M. Tonato, R. Canaletti, C. Boni, F. Buzzi, G. Ceci, E. Corgna, R. Lottici, F. Papadia, M. Sofra, and M. Bacchi, DTIC Vs DTIC plus tamoxifen in metastatic malignant melanoma — A perspective randomized trial of the italian oncology group for clinical research, 2nd Int. Conf. on Melanoma, Venice 16–19 oct. 1989, Abst. pg. 325.

    Google Scholar 

  33. C.J. Rosenthal, A. Ohri and M. Rothman, Phase I study of DTIC by continuous infusion and concomitant radiation therapy, ASCO Proc. 6: 43 (1987).

    Google Scholar 

  34. D.B. Thomson, R.C. McLeod, and P. Hersey, Phase I/II study of tolerability and efficacy of recombinant interferon with dacarbazine in advanced malignant melanoma, ASCO Proc. 6: 208 (1987).

    Google Scholar 

  35. E. Bajetta, E. Negretti, B. Giannotti, L. Brogelli, I. Brunetti, M.R. Sertoli, M.G. Bernengo, M.C. Sofra, G. Maifredi, G. Zumiani, G. Cornella, R. Buzzoni, and N. Cascinelli, Phase II study of interferon alpha 2-a and dacarbazine (DTIC) in metastatic melanoma, ASCO Proc. 8: 286 (1989).

    Google Scholar 

  36. R. Kerr, P. Pippen, R. Mennel, and S. Jones, Treatment of metastatic malignant melanoma with a combination of interferon alpha 2-a (Roferon) and dacarbazine (DTIC), ASCO Proc. 8: 288 (1989).

    Google Scholar 

  37. N.E.J. Papadopoulos, J. Howard, J.L. Murray, C. Plager, S. Legna, J. Reuben, J.U. Gutterman, and R.S. Benjamin, Phase I–II DTIC and interleukin-2 (IL-2) trial for metastatic malignant melanoma, ASCO Proc. 8: 290 (1989).

    Google Scholar 

  38. D.A. Vorobiof and G. Falkson, DTIC versus DTIC and recobinant interferon α2b in the treatment of patients with advanced malignant melanoma, 5t h Europ. Conf. Clin. Oncol. ECCO5, London 3–7 sept. 1989, Abst. O-0714

    Google Scholar 

  39. G. Sava, T. Giraldi, L. Perissin, S. Zorzet, F. Mallardi, and V. Grill, Infiltration of the liver and brain by tumor cells in leukemic mice: prevention by dimethyltriazenes and cyclophosphamide, Tumori 70: 477 (1984).

    PubMed  CAS  Google Scholar 

  40. T. Giraldi, G. Sava, E. Mitri, and R. Cherubino, Hemostasis and mechanism of action of selective antimetastatic drugs in mice bearing Lewis lung carcinoma, Eur. J. Cancer Clin. Oncol. 20: 961 (1984).

    Article  PubMed  CAS  Google Scholar 

  41. G. Sava, T. Giraldi, L. Lassiani, and C. Nisi, Antimetastatic action and hematological toxicity of p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide used as prophylactic adjuvants to surgical tumor removal in mice bearing B16 melanoma, Cancer Res. 44: 64 (1984).

    PubMed  CAS  Google Scholar 

  42. M.S. Mitchell, M.B. Mokyr, and J.M. Davis, Effect of chemotherapy and immunotherapy on tumor specific immunity in melanoma, J. Clin. Invest. 59: 1017 (1977).

    Article  PubMed  CAS  Google Scholar 

  43. J. Berkelhammer, M.J. Mastrangelo, R.E. Bellet, and R.T. Prehn, Chemoimmunotherapy increases the lymphocyte reactivity of melanoma patients, J. Cancer Clin. Oncol. 15: 197 (1979).

    CAS  Google Scholar 

  44. G. Cartei, T. Giraldi and R. Carrella, Effects of dacarbazine (DTIC) on immunology in the human. I: high intermittent dose (HID), International Conference on Triazenes; Chemical, Biological and Clinical Aspects, Trieste 28–29 nov. 1989, Abst. P2, in press

    Google Scholar 

  45. G. Cartei, T. Giraldi and R. Carrella, Effects of dacarbazine (DTIC) on immunology in the human. II: low and intermediate chronic dose schedule, International Conference on Triazenes; Chemical, Biological and Clinical Aspects, Trieste 28–29 nov. 1989, Abst. P3, in press

    Google Scholar 

  46. U. Veronesi, C. Aubert, E. Bajetta, G. Beretta, G. Bonadonna, N. Cascinelli, J. De Marsillac, R.L. Ikonopisov, B. Kiss, T. Krementz, F. Lejeune, Z. Mechi, G.W. Milton, A. Morabito, P. Mulder, P. Pawlicki, J. Priario, P. Rumke, R. Sertoli, R. Tomin, N. Trapeznikov, and R. Wagner, (WHO collaborating centres for evaluation of methods of diagnosis and treatment of melanoma) controlled study with imidazole carboxamide (DTIC), DTIC + Bacillus Calmette Guerin (BCG) and DTIC + Corynebacterium parvum in advanced melanoma, Tumori 70: 41 (1984).

    Google Scholar 

  47. F.J. Lejeune, Malignant melanoma, in: “Randomized trials in cancer, a critical review by sites,” M.L. Slevin and M.J. Staquet, eds., Raven Press, New York (1986).

    Google Scholar 

  48. R.L. Comis, DTIC (NSC 45388) in malignant melanoma, a propsective. Cancer Treat. Rep. 60: 165 (1976).

    PubMed  CAS  Google Scholar 

  49. G.M.B. Durie, L. Clouse, T. Braich, M. Grimm, and A.B. Robertone, Intereferon alpha2b and cyclophosphamide combination studies: in vitro and phase I–II clinical results, Seminars Oncology 13: 84 (1986).

    CAS  Google Scholar 

  50. G. Zupi, A. Corsi, A. Sacchi, L. Lassiani, and T. Giraldi, Effects of dimethyltriazenes on in vitro Lewis lung carcinoma lines with different metastatic capacity, Invasion Metastasis 4: 179 (1984).

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Divisione di Oncologia, Ospedale Civile di Udine Piazza Santa Maria della Misericordia, I-33110, Udine, Italy

    G. Cartei

Authors
  1. G. Cartei
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Istituto di Farmacologia, Università di Trieste, 34127, Trieste, Italy

    Tullio Giraldi

  2. Toxicology Unit, Medical Research Council, Woodmansterne Road, SM5 4EF, Carshalton, Surrey, UK

    Thomas A. Connors

  3. Divisione di Oncologia Medica, Ospedale S. Maria della Misericordia, 33100, Udine, Italy

    Giuseppe Cartei

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer Science+Business Media New York

About this chapter

Cite this chapter

Cartei, G. (1990). Triazenes: Therapeutic Considerations and Perspectives. In: Giraldi, T., Connors, T.A., Cartei, G. (eds) Triazenes. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3832-5_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-3832-5_11

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6710-9

  • Online ISBN: 978-1-4615-3832-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation